Compare Gilead Sciences, Inc. (GILD) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Gilead Sciences, Inc. trades at $151.02 (market cap $182.40B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.19 (market cap $560.32M). The key difference: Gilead Sciences, Inc. is far larger — about 325.5× Direxion Daily FTSE China Bull 3x Shares's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Direxion Daily FTSE China Bull 3x Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| GILD | YINN | |
|---|---|---|
Market Cap | $182.40B | $560.32M |
Volume | 4,469,821 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $52.69 |
52-Week Low | $116.74 | $21.45 |
Typical Hold Time | 111 Days | 25 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
YINN is trading at $25.09, up 6.49% in the past 24 hours, though technical indicators signal a bearish trend with 17 sell signals versus 2 buy signals. The stock faces resistance at $24 with support at $23. Recent news highlights China's economic policies and export controls, which may impact the underlying index exposure. Financial ratios remain unavailable for analysis.
The outlook is cautious due to bearish technicals and China-related macroeconomic risks. Opportunities exist if support holds and sentiment improves, but investors face volatility from regulatory developments and weak momentum. Risk management is essential given the conflicting signals between price action and technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
